Pfizer’s Paxlovid study fails to answer key questions over benefit for broader populations

Pfizer’s Paxlovid study fails to answer key questions over benefit for broader populations

Pfizer said Tuesday that a much-watched study of its antiviral Paxlovid in patients who have Covid but don’t have risk factors for severe disease failed to show a benefit in speeding alleviation of Covid symptoms, but did seem to prevent doctor’s visits and hospitalizations. Additionally, because of the small number of hospitalizations overall in the …

Pfizer’s Paxlovid study fails to answer key questions over benefit for broader populations Read More »